MAP2K3 and neoplasm: These findings reveal a potential additive effect of MKK3 depletion on tumor cell response to drugs, thus pointing at MKK3 as a novel potential clinical target to improve both wtp53 and mutp53 cancer cell response to chemotherapeutic agents.